Skip to content
10-Q

Quarterly Report

Astria Therapeutics, Inc.

0001410578-24-001308

← back to feed
Filed
Aug 12, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Jul 31, 2024 56.43M sh
Short Term Investments Q2 2024 · Jun 30, 2024 $267.49M
Short Term Investments Q2 2024 · Dec 31, 2023 $71M
Current Liabilities Q2 2024 · Jun 30, 2024 $16.37M
Current Liabilities Q2 2024 · Dec 31, 2023 $11.55M
Total Liabilities Q2 2024 · Jun 30, 2024 $20.91M
Total Liabilities Q2 2024 · Dec 31, 2023 $11.55M
Current Assets Q2 2024 · Jun 30, 2024 $357.89M
Current Assets Q2 2024 · Dec 31, 2023 $250.94M
Total Assets Q2 2024 · Jun 30, 2024 $367.99M
Total Assets Q2 2024 · Dec 31, 2023 $254.67M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $175.53M
Cash And Equivalents Q2 2024 · Jun 30, 2023 $133.96M
Shares Diluted Q2 2024 · Jun 30, 2023 28.02M sh
Shares Diluted Q2 2024 · Jun 30, 2023 27.98M sh
Capex Q2 2024 · Jun 30, 2023 $5K
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$23.95M
Stockholders Equity Q2 2024 · Jun 30, 2023 $200.4M
Stockholders Equity Q2 2024 · Mar 31, 2023 $211.36M
Stockholders Equity Q2 2024 · Dec 31, 2022 $221.22M
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.45
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.85
Eps Basic Q2 2024 · Jun 30, 2023 −$0.45
Eps Basic Q2 2024 · Jun 30, 2023 −$0.85
Sga Expense Q2 2024 · Jun 30, 2023 $6.01M
Sga Expense Q2 2024 · Jun 30, 2023 $11.47M
Net Income Q2 2024 · Jun 30, 2023 −$12.57M
Net Income Q2 2024 · Jun 30, 2023 −$23.75M
Net Income Q2 2024 · Mar 31, 2023 −$11.19M
Operating Income Q2 2024 · Jun 30, 2023 −$15.1M
Operating Income Q2 2024 · Jun 30, 2023 −$28.6M